Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 11:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–8 of 8 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Onychomycosis/Onycholysis and Tinea Pedis
Interventions
Placebo, Terbinafine Hydrochloride, Terbinafine
Drug
Lead sponsor
NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)
Industry
Eligibility
18 Years to 70 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Paramus, New Jersey
Conditions
Healthy
Interventions
Terbinafine Hydrochloride Tablets 250 mg, Lamisil® Tablets 250 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Fargo, North Dakota
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Terbinafine Tablets Under Fasting Conditions

NCT00602342
Conditions
Onychomycosis
Interventions
Terbinafine
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Saint Charles, Missouri
Conditions
Ankylosing Spondylitis, Axial Spondyloarthritis, Psoriatic Spondylitis, Spondylitis Secondary to Inflammatory Bowel Disease, Axial Spondyloarthopathy
Interventions
Terbinafine Tablets, Laboratory Testing
Drug · Diagnostic Test
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Terbinafine Tablets Under Fed Conditions

NCT00602251
Conditions
Onychomycosis
Interventions
Terbinafine
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Saint Charles, Missouri
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Terbinafine HCl 250 mg Tablet Formulations Under Non-Fasting Conditions

NCT00833664
Conditions
Healthy
Interventions
Terbinafine HCl 250mg tablets, Lamisil® 250 mg Tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Terbinafine HCl 250 mg Tablet Under Fasting Conditions

NCT00833586
Conditions
Healthy
Interventions
Terbinafine HCl 250mg tablets, Lamisil® 250 mg Tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Healthy
Interventions
Terbinafine Hydrochloride Tablets 250 mg, Lamisil® Tablets 250 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Fargo, North Dakota